Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:41:06.638Z.
Calculation as of: 2026-10-06T22:41:06.638Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea268c636d02c1563f9a0cc17fa45ef3048b6802d4031696aa30e1bc9d7aaf2a
PEG RATIO
N/A
Connect Biopharma Holdings Limited
Market Cap
$57.01M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $57.01M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A |
| Aldeyra The (ALDX)vs › | $55.25M | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
